EP1722778A1 - Methods and compositions for the treatment of lipodystrophy - Google Patents

Methods and compositions for the treatment of lipodystrophy

Info

Publication number
EP1722778A1
EP1722778A1 EP05707019A EP05707019A EP1722778A1 EP 1722778 A1 EP1722778 A1 EP 1722778A1 EP 05707019 A EP05707019 A EP 05707019A EP 05707019 A EP05707019 A EP 05707019A EP 1722778 A1 EP1722778 A1 EP 1722778A1
Authority
EP
European Patent Office
Prior art keywords
statin
growth hormone
hgh
lipodystrophy
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05707019A
Other languages
German (de)
English (en)
French (fr)
Inventor
Giampiero De Luca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of EP1722778A1 publication Critical patent/EP1722778A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP05707019A 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy Withdrawn EP1722778A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54020404P 2004-01-29 2004-01-29
US54336604P 2004-02-10 2004-02-10
PCT/EP2005/000758 WO2005074916A1 (en) 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
EP1722778A1 true EP1722778A1 (en) 2006-11-22

Family

ID=34841102

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05707019A Withdrawn EP1722778A1 (en) 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy

Country Status (10)

Country Link
EP (1) EP1722778A1 (ja)
JP (1) JP2007519669A (ja)
KR (1) KR20060127977A (ja)
AU (1) AU2005210093A1 (ja)
BR (1) BRPI0507302A (ja)
CA (1) CA2552404A1 (ja)
EA (1) EA200601392A1 (ja)
IL (1) IL176762A0 (ja)
NO (1) NO20063279L (ja)
WO (1) WO2005074916A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803623D0 (sv) * 1998-10-22 1998-10-22 Sahltech Ab New therapeutic application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005074916A1 *

Also Published As

Publication number Publication date
WO2005074916A1 (en) 2005-08-18
NO20063279L (no) 2006-09-19
JP2007519669A (ja) 2007-07-19
KR20060127977A (ko) 2006-12-13
CA2552404A1 (en) 2005-08-18
EA200601392A1 (ru) 2006-12-29
AU2005210093A1 (en) 2005-08-18
IL176762A0 (en) 2006-10-31
BRPI0507302A (pt) 2007-06-26

Similar Documents

Publication Publication Date Title
US20070161551A1 (en) Methods and compositions for the treatment of lipodystrophy
KR101383493B1 (ko) 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제
US6939853B2 (en) Combined use of a GLP-1 compound and another drug for treating dyslipidemia
EP1461070B1 (en) Combined use of a glp-1 compound and an aldose reductase inhibitor
EP0944396B1 (en) Compositions and methods for enhancing intestinal function
US20080004217A1 (en) Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
US20170319664A1 (en) Dosing regimen
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2310042B1 (en) Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
EP0766966A2 (en) Method of treating insulin resistance
JPH11505265A (ja) Ｉｇｆ−ｉの投与法
WO2005074916A1 (en) Methods and compositions for the treatment of lipodystrophy
JP2004518756A (ja) Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
US20070275877A1 (en) Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
US20070037861A1 (en) Enhanced method of treatment of growth disorders
MXPA06007761A (en) Methods and compositions for the treatment of lipodystrophy
CN1917871A (zh) 治疗脂肪营养不良的方法和组合物
JP2000191549A (ja) Ｈｉｖに関連した異形症／代謝不全症候群の治療
MXPA06002948A (en) Enhanced method of treatment of growth disorders
JPH07316071A (ja) 筋ジストロフィー治療薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LABORATOIRES SERONO SA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090801